Alice Fachin

Dr. Alice Fachin


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MLMarianna Lucafò
Marianna Lucafò
CBCarlotta Bidoli
Carlotta Bidoli
MFMartina Franzin
Martina Franzin
EEErez Eitan
Erez Eitan
SRSara Rau
Sara Rau
GCGiorgio Cozzi
Giorgio Cozzi
Ketamine provides the highest safety profile among sedatives for procedural sedation and analgesia in the pediatric emergency setting. However, it can cause vomiting and recovery agitation. No studies have examined epigenetic factors, such as microRNAs, for predicting the occurrence of these adverse events. Neuronal‐derived extracellular vesicle microRNA profiles were studied to predict the occurrence of ketamine‐induced vomiting and recovery agitation in children. For this aim, a single‐center prospective pharmacoepigenetic study was performed and 50 children who underwent procedural sedation with intravenous ketamine as the only sedative drug were enrolled between October 2019 and November 2022. MiRNA profiling in plasma neural‐derived extracellular vesicles was analyzed through next‐generation sequencing and measured before treatment with ketamine. Twenty‐two patients experienced vomiting or recovery agitation. Among the 16 differentially expressed microRNAs, the upregulated miR‐15a‐5p and miR‐484 targeted genes related to N‐methyl‐D‐aspartate (NMDA) receptor activity, including glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A). Preliminary data confirmed lower GRIN2A levels in patients who developed these events. Downregulated miR‐126‐3p and miR‐24‐3p targeted AMPA receptor‐associated genes. Functional analyses of gene targets revealed the enrichment of glutamatergic and neurotrophins signaling. Recovery agitation was associated with this network. Vomiting was related to dopaminergic and cholinergic systems. Three miRNAs (miR‐18a‐3p, miR‐484, and miR‐548az‐5p) were identified as predictive biomarkers (AUC 0.814; 95% CI: 0.632–0.956) for ketamine‐induced vomiting and recovery agitation. MicroRNA profiles can predict the development of ketamine‐induced vomiting or recovery agitation in children. This study contributes to the understanding of the mechanisms underlying ketamine‐induced adverse events.

27 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AFAlice Fachin
Alice Fachin
CCChiara De Carlo
Chiara De Carlo
AMAlessandra Maestro
Alessandra Maestro
DZDavide Zanon
Davide Zanon
EBEgidio Barbi
Egidio Barbi
Natalia MaximovaNatalia Maximova
Natalia Maximova
Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by the U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years and older. Its role as a triglyceride-lowering drug is also emerging in the literature. However, it has not been approved for this indication yet, neither in the adult nor in the pediatric population. We describe the case of a 10-year-old boy who underwent an allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia complicated by chronic graft-versus-host disease (GVHD) and presented life-threatening refractory hypertriglyceridemia due to the concomitant use of ruxolitinib and sirolimus. After the failure of the insulin treatment and due to the technical impossibility of performing lipid apheresis, the child underwent evinacumab treatment, obtaining a dramatic rapid reduction in triglyceride and cholesterol levels. This is the first report of a pediatric patient younger than 12 years in Europe receiving evinacumab to treat severe hypertriglyceridemia. The therapy with angiopoietin-like proteins inhibitors has been effective, safe, and well-tolerated in our patient, suggesting that evinacumab may be used in the pediatric population when other therapeutic strategies are ineffective or contraindicated.

31 January 2026 in Endocrine Practice
Verified
Journal Article
Open access
IAIlen Lucia Guerrero Almeida
Ilen Lucia Guerrero Almeida
AFAlice Fachin
Alice Fachin
ECEulalia Catamo
Eulalia Catamo
ARAntonietta Robino
Antonietta Robino
PDPaolo Dalena
Paolo Dalena
GTGianluca Tornese
Gianluca Tornese
To assess public knowledge of type 1 diabetes (T1D), awareness of the newly introduced Italian national T1D pediatric screening program, and willingness to participate in screening among survey respondents. By a nationwide cross-sectional online survey demographic data and T1D knowledge, awareness and attitudes toward the screening program were collected. A composite T1D knowledge score (range -1 to +1) was calculated using a right-minus-wrongs method. A total of 695 respondents participated. Although 93.4% had heard of diabetes, specific knowledge of T1D was limited, with a median T1D knowledge score of 0.45. Significantly higher scores (p-value<0.05) were observed among females, residents of pilot regions, healthcare workers, and individuals who knew someone with diabetes. Awareness of the screening program is modest, with only 35.8% of participants adequately informed, with higher percentage in pilot regions (54.3%). Despite limited awareness, willingness to screen was high, with 93.4% of respondents and 95.4% of parents of eligible children open to screening. Higher knowledge scores were associated with greater willingness (p-value=0.037). Results highlight strong public readiness for T1D screening, but significant gaps in knowledge and awareness. Targeted education and communication are needed to ensure informed participation and support successful nationwide implementation of the program.

11 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
AFAlice Fachin
Alice Fachin
CCChiara De Carlo
Chiara De Carlo
AMAlessandra Maestro
Alessandra Maestro
DZDavide Zanon
Davide Zanon
EBEgidio Barbi
Egidio Barbi
Natalia MaximovaNatalia Maximova
Natalia Maximova
Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years and older. Its role as a triglyceride-lowering drug is also emerging in the literature. However, it has not been approved for this indication yet, neither in the adult nor in the pediatric population. We describe the case of a 10-year-old boy who underwent an allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia complicated by chronic graft–versus–host disease (GVHD) and presented life-threatening refractory hypertriglyceridemia due to the concomitant use of ruxolitinib and sirolimus. After the failure of the insulin treatment and due to the technical impossibility of performing lipid apheresis, we underwent the child to evinacumab treatment, obtaining a dramatic rapid reduction in triglyceride and cholesterol levels. This is the first report of a pediatric patient younger than 12 years in Europa receiving evinacumab to treat severe hypertriglyceridemia. The therapy with angiopoietin-like proteins inhibitors has been effective, safe, and well-tolerated in our patient, suggesting that evinacumab may be used in the pediatric population when other therapeutic strategies are ineffective or contraindicated.

28 May 2026 in Endocrine
Verified
Journal Article
Open access
CRChiara Rodaro
Chiara Rodaro
GTGianluca Tamaro
Gianluca Tamaro
AFAlice Fachin
Alice Fachin
FNFrancesca Nicolardi
Francesca Nicolardi
STSilvia Tommasi
Silvia Tommasi
GTGianluca Tornese
Gianluca Tornese
Growth hormone deficiency (GHD) in childhood and adolescence requires long-term therapy with recombinant human growth hormone (rhGH). Although daily injections are highly effective, they impose a considerable treatment burden that often leads to suboptimal adherence and compromised growth outcomes. Reported non-adherence rates vary widely, largely due to heterogeneous definitions and assessment methods. Adherence is influenced by multiple factors, including device usability, psychosocial context, family engagement, and the level of support from health care professionals. Although Long-Acting Growth Hormone (LAGH) preparations, administered once weekly, have demonstrated efficacy and safety comparable to daily rhGH in clinical trials, adherence in these settings may be overestimated. The key question now is whether LAGH can truly enhance treatment adherence in real-world settings. This narrative review summarizes the very limited data currently available on adherence to LAGH in both treatment-naïve patients and those switching from daily rhGH, highlighting methodological heterogeneity and the absence of robust long-term outcomes. Rather than providing definitive conclusions, our aim is to map existing evidence, identify critical gaps, and outline priorities for future real-world and longitudinal studies evaluating adherence, persistence, and clinical consequences of poor adherence in LAGH users.

7 April 2026 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
MPMaria Chiara Pellegrin
Maria Chiara Pellegrin
GTGianluca Tamaro
Gianluca Tamaro
AFAlice Fachin
Alice Fachin
EBEgidio Barbi
Egidio Barbi
GTGianluca Tornese
Gianluca Tornese
Turner syndrome (TS) often presents with subtle or overlooked clinical signs, contributing to frequent diagnostic delays. We describe the case of a 13‐year‐old girl referred for short stature whose only remarkable physical findings were the absence of the fourth and fifth knuckles on both hands—known as Archibald's metacarpal sign—and a short fourth metatarsal. Growth had decelerated after spontaneous menarche, and previous examinations had not recognized these skeletal clues. Radiographs confirmed short fourth and fifth metacarpals. Karyotype analysis identified a complete deletion of the short arm of one X chromosome (Xp), consistent with TS. Further evaluation revealed a bicuspid aortic valve, autoimmune thyroiditis with subclinical hypothyroidism, and reduced ovarian reserve. Archibald's sign, caused by SHOX haploinsufficiency, is present in about one‐third of individuals with TS but may also appear in other disorders or even healthy individuals. This case highlights the diagnostic value of careful physical examination in girls with short stature. Recognizing seemingly minor skeletal findings can prompt timely karyotyping, allowing earlier detection of TS and appropriate long‐term management.